Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
about
Activation receptor-induced tolerance of mature NK cells in vivo requires signaling through the receptor and is reversibleUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsPathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationNatural Killer Cell Recognition of Melanoma: New Clues for a More Effective ImmunotherapyImproving natural killer cell cancer immunotherapyAltered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells.A soluble fragment of the tumor antigen BCL2-associated athanogene 6 (BAG-6) is essential and sufficient for inhibition of NKp30 receptor-dependent cytotoxicity of natural killer cellsLow NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia.Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognitionEffects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies.Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DCTranscript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging.Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.Recognition of tumors by the innate immune system and natural killer cells.NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities.CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemiaSecreted β3-integrin enhances natural killer cell activity against acute myeloid leukemia cells.Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1.Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityB7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity.Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer.Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.Human herpesviridae methods of natural killer cell evasionPotential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes.Increased NK Cell Maturation in Patients with Acute Myeloid LeukemiaRole of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia.NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells.Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damageIdentification of human NK cells that are deficient for signaling adaptor FcRγ and specialized for antibody-dependent immune functionsRepression of GSK3 restores NK cell cytotoxicity in AML patients.Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemiaNK cell receptors and their ligands in leukemia.
P2860
Q24611294-A1288045-B0C0-4B51-BBBA-11FF2526B96EQ26751011-ECBC60A0-7B75-4B36-A802-6E18675F1270Q26765345-DEEF1D57-D7A4-412D-AA84-4FDE649E813BQ26771449-AB548130-0DF2-4471-96DD-69E189D69E4BQ28087719-F35E0931-C64B-4A45-8843-D4BE6162A5D6Q30364263-7C0A0110-8B17-48E2-AECB-8CCB7E2B0CC5Q33292224-EF0F29DF-391F-432A-998D-575FAFB10EEFQ33468660-6FFFFE51-9B94-4C6D-B609-0C4E30F9CC88Q33558780-4BB54F9B-8F79-49D6-9B54-876F1C3F9DFDQ33593877-CBE281BD-4FD7-4FB8-B5A4-8EDB7FA0AFE7Q33688517-F99DA0B7-B257-4E0E-BFB2-1E012A370C91Q33734571-FB39AFA3-4985-426C-8814-5398753E7F82Q33761979-BA08C8F5-9B46-4ED4-9C7D-A30F72FEB75EQ33777096-9802B32B-E76B-4A60-B9AA-91355B9D4784Q33940675-E0AE0DC5-A5EC-4864-ADDB-F8BC7DC633ACQ34003558-E488E6AB-0E48-4E14-86A0-79310944AF29Q34016504-4CE9F34A-A250-4610-87A7-95C97C9E3A53Q34496462-6FEF7DB7-7C5B-49BA-8680-4B8F95ED785EQ34615804-37727950-1CED-48D4-B409-9FE0C976C088Q34786615-A7B1E887-E9FE-4DBD-A66A-56F8640DB900Q34977414-587F2215-C7A3-4875-A6AC-A2727979564EQ35185573-CEA99D29-A811-401E-8806-8CCAF0CE770FQ35193728-813E4935-8C3B-4D86-A041-1878B8B85BBDQ35208414-0A7AE25A-57DA-4A33-8147-030F4481B2C9Q35553553-403C9E56-2B77-4399-984C-76E2F015F80BQ35613233-3162CD38-15CB-4E26-B460-4FDFEA89D2F7Q35929030-E06D1261-7C78-4BCF-BA94-CF370248CBADQ35987354-96A1C665-1DE3-440E-A90E-8E7B29BD7359Q36057599-B7A66400-C91E-4BCB-B07F-461E195FBD3AQ36102137-D8A0F667-AEB1-48EE-BFA1-DCE7969A32ECQ36245682-B1815D4A-6196-4124-A487-E4DB627EC288Q36256263-458AF6C2-58E0-468B-8661-BB325F621D5AQ36597388-44DC7736-3AA0-4267-9746-857A0D1FEA59Q36618933-F33AA36A-AEF9-476D-8391-5123FDE1F8CEQ36701917-95D6EC76-B39A-4CE7-AEA6-6E38116A0F44Q36739038-8C6AA27C-8DB9-4B92-A2F1-A2C531093651Q36752738-31CEE8E9-3200-4FD9-92CB-4FF940E3EABFQ36768725-AE972A09-F1D1-4696-B262-333D4653107EQ36979119-454EB506-7C8C-4E9D-9DC2-CF8162C86D70Q37018656-C1189868-84E4-42F9-9F3F-D00A5089B43C
P2860
Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@en
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@nl
type
label
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@en
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@nl
prefLabel
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@en
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@nl
P2093
P1433
P1476
Deficient expression of NCR in ...... n NCRdull phenotype induction.
@en
P2093
Christine Arnoulet
Daniel Olive
Danielle Sainty
Françoise Mallet
Sylvaine Just-Landi
P304
P356
10.1182/BLOOD-2005-08-027979
P407
P577
2006-08-29T00:00:00Z